Future studies should prioritize multicenter cohorts to validate PDA and thromboembolism as risk factors, mechanistic investigations of genetic or inflammatory pathways (e.g., RARG or VEGF signaling), and longitudinal designs to assess late-onset toxicity. Here, RARG is linked to Patent ductus arteriosus.